title: Saudi practical guidelines on biologic treatment of psoriasis.
abstract: The current treatment of psoriasis patients with biologic agents in the Kingdom of Saudi Arabia (KSA) is mainly based on clinical experience. Although there are published international guidelines for treatment with biologics, such as the European S3 guidelines (a joint project of the European Dermatology Forum, the European Academy of Dermatology and Venereology, and the International Psoriasis Council), many nations have found it beneficial to develop country-based guidelines that incorporate specific regional aspects of therapy (legal and practical). With the expanded role of biologic agents in the treatment of psoriasis in Saudi Arabia, a need for local Saudi guidelines has become evident. Here we present a practical approach to the evidence-based clinical administration of biologics for professionals who treat patients with psoriasis.
authors: King Faisal Specialist Hospital & Research Centre , Riyadh , Saudi Arabia .
authors: Issam R
authors: IR
authors: Hamadah
authors: Ali A
authors: AA
authors: Al Raddadi
authors: Khalid A
authors: KA
authors: Bahamdan
authors: Mohammad I
authors: MI
authors: Fatani
authors: Ali
authors: A
authors: Alnahdi
authors: Abdullah M
authors: AM
authors: Al Rakban
authors: Abdullah
authors: A
authors: Alkhalifah
authors: Ali
authors: A
authors: Al Ameer
authors: Yasir H
authors: YH
authors: Shaikh
authors: Ayman M
authors: AM
authors: Elgendi
authors: Abdulrahman Y
authors: AY
authors: Al Zoman
authors: Khalid A
authors: KA
authors: Alafif
mesh_terms: D001688:Biological Products / Q000627:therapeutic use*; D003880:Dermatology / Q000379:methods; D006801:Humans; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000188:drug therapy*; D012529:Saudi Arabia
chemical_list: D001688:Biological Products
keywords: Adalimumab; etanercept; infliximab; psoriatic arthritis; ustekinumab